Literature DB >> 28693260

MicroRNA expression profiling in patients with hepatocellular carcinoma of familial aggregation and hepatitis B virus infection.

Er-Lei Zhang1, Jin Gu1, Zun-Yi Zhang1, Ke-Shuai Dong1, Bin-Yong Liang1, Zhi-Yong Huang1.   

Abstract

Numerous studies have suggested that microRNAs (miRNAs) potently affect hepatocarcinogenesis. However, the miRNA expression profiling in patients with hepatocellular carcinoma (HCC) of familial aggregation and hepatitis B virus (HBV) infection has not been elucidated. In the present study, the plasma miRNA expression profiles of 3 patients with HCC with familial aggregation of HCC and HBV infection and 1 healthy volunteer were examined by microarray analysis, in order to identify relevant miRNAs involved in the pathogenesis of HCC with familial aggregation and HBV infection. The results indicated that 26 miRNAs exhibited a ≥20-fold increase or decrease in the plasma of patients with HCC, compared with the healthy control (24 upregulated and 2 downregulated). Among these altered miRNAs, 15 of them have been reported in HCC. The other 11 miRNAs have never been reported in HCC. These differentially-expressed miRNAs may be potential molecular markers for HCC pathogenesis and development.

Entities:  

Keywords:  familial aggregation; hepatitis B virus; hepatocellular carcinoma; microRNA; microarray profiling

Year:  2017        PMID: 28693260      PMCID: PMC5494791          DOI: 10.3892/ol.2017.6178

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  50 in total

1.  Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3.

Authors:  Yu Wang; Yiwei Lu; Soo Ting Toh; Wing-Kin Sung; Patrick Tan; Pierce Chow; Alexander Y F Chung; London L P Jooi; Caroline G L Lee
Journal:  J Hepatol       Date:  2010-04-02       Impact factor: 25.083

2.  Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Farah Logna; Bin Bao; Philip A Philip; Murray Korc; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

3.  Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice.

Authors:  Marie Anson; Anne-Marie Crain-Denoyelle; Véronique Baud; Fanny Chereau; Angélique Gougelet; Benoit Terris; Satoshi Yamagoe; Sabine Colnot; Mireille Viguier; Christine Perret; Jean-Pierre Couty
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

4.  Family history of liver cancer and hepatocellular carcinoma.

Authors:  Federica Turati; Valeria Edefonti; Renato Talamini; Monica Ferraroni; Matteo Malvezzi; Francesca Bravi; Silvia Franceschi; Maurizio Montella; Jerry Polesel; Antonella Zucchetto; Carlo La Vecchia; Eva Negri; Adriano Decarli
Journal:  Hepatology       Date:  2012-03-21       Impact factor: 17.425

5.  Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xufu Wei; Cui Tan; Chengyong Tang; Guosheng Ren; Tingxiu Xiang; Zhu Qiu; Rui Liu; Zhongjun Wu
Journal:  Cell Signal       Date:  2013-01-30       Impact factor: 4.315

6.  miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A.

Authors:  Xufu Wei; Tingxiu Xiang; Guosheng Ren; Cui Tan; Rui Liu; Xiao Xu; Zhongjun Wu
Journal:  Cell Signal       Date:  2012-11-01       Impact factor: 4.315

7.  miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression.

Authors:  Hongtuan Zhang; Shiyong Qi; Tao Zhang; Andi Wang; Ranlu Liu; Jia Guo; Yuzhuo Wang; Yong Xu
Journal:  Oncotarget       Date:  2015-03-20

Review 8.  MicroRNAs associated with HBV infection and HBV-related HCC.

Authors:  Kun-Lin Xie; Yan-Ge Zhang; Jun Liu; Yong Zeng; Hong Wu
Journal:  Theranostics       Date:  2014-09-19       Impact factor: 11.556

9.  miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN.

Authors:  Mengyang Zhao; Rongcheng Luo; Yiyi Liu; Linyuan Gao; Zhaojian Fu; Qiaofen Fu; Xiaojun Luo; Yiyu Chen; Xiaojie Deng; Zixi Liang; Xin Li; Chao Cheng; Zhen Liu; Weiyi Fang
Journal:  Nat Commun       Date:  2016-04-20       Impact factor: 14.919

10.  miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma.

Authors:  Lei Yu; Xuejun Gong; Lei Sun; Hong Yao; Baoling Lu; Liying Zhu
Journal:  Oncotarget       Date:  2015-11-17
View more
  4 in total

1.  Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.

Authors:  Ravneet Chhabra; Stephanie Rockfield; Jennifer Guergues; Owen W Nadeau; Robert Hill; Stanley M Stevens; Meera Nanjundan
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

2.  The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer.

Authors:  Ali Zare; Alireza Ahadi; Pegah Larki; Mir Davood Omrani; Mohammad Reza Zali; Nasser Malekpour Alamdari; Hamid Ghaedi
Journal:  Mol Biol Rep       Date:  2018-08-31       Impact factor: 2.316

3.  Clinical significances and diagnostic utilities of both miR-215 and squamous cell carcinoma antigen-IgM versus alpha-fetoprotein in Egyptian patients with hepatitis C virus-induced hepatocellular carcinoma.

Authors:  Lamia H Ali; Aliaa M Higazi; Hend M Moness; Naglaa M Farag; Zienab M Saad; Hamdy A Moukareb; Wael Soliman; Ghada El Sagheer; Sahar R Abd El Hamid; Haytham Abdl Hamid
Journal:  Clin Exp Gastroenterol       Date:  2019-02-01

4.  Comprehensive transcriptomic analyses of tissue, serum, and serum exosomes from hepatocellular carcinoma patients.

Authors:  Robin Mjelle; Simona O Dima; Nicolae Bacalbasa; Konika Chawla; Andrei Sorop; Dana Cucu; Vlad Herlea; Pål Sætrom; Irinel Popescu
Journal:  BMC Cancer       Date:  2019-10-28       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.